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background
Guidelines propose classification of conventional blood pressure (CBP) 
into normotension (<120/<80 mm Hg), prehypertension (120–139/80–
89 mm Hg), and hypertension (≥140/≥90 mm Hg).
methods
To assess the potential differential contribution of ambulatory blood 
pressure (ABP) in predicting risk across CBP strata, we analyzed out-
comes in 7,826 untreated people recruited from 11 populations.
results
During an 11.3-year period, 809 participants died (276 cardiovascular 
deaths) and 639, 383, and 225 experienced a cardiovascular, cardiac, 
or cerebrovascular event. Compared with normotension (n = 2,639), 
prehypertension (n = 3,076) carried higher risk (P ≤ 0.015) of cardio-
vascular (+41%) and cerebrovascular (+92%) endpoints; compared 
with hypertension (n  =  2,111) prehypertension entailed lower risk 
(P ≤ 0.005) of total mortality (–14%) and cardiovascular mortality 
(–29%) and of cardiovascular (–34%), cardiac (–33%), or cerebrovas-
cular (–47%) events. Multivariable-adjusted hazard ratios (HRs) for 
stroke associated with 24-hour and daytime diastolic ABP (+5 mm Hg) 
were higher (P ≤ 0.045) in normotension than in prehypertension and 
hypertension (1.98 vs.1.19 vs.1.28 and 1.73 vs.1.09 vs. 1.24, respec-
tively) with similar trends (0.03 ≤ P ≤ 0.11) for systolic ABP (+10 mm 
Hg). However, HRs for fatal endpoints and cardiac events associated 
with ABP did not differ significantly (P ≥ 0.13) across CBP catego-
ries. Of normotensive and prehypertensive participants, 7.5% and 
29.3% had masked hypertension (daytime ABP ≥135/≥85 mm Hg). 
Compared with true normotension (P ≤ 0.01), HRs for stroke were 3.02 
in normotension and 2.97 in prehypertension associated with masked 
hypertension with no difference between the latter two conditions 
(P = 0.93).
conclusion
ABP refines risk stratification in normotension and prehypertension 
mainly by enabling the diagnosis of masked hypertension.
Keywords: ambulatory blood pressure monitoring; blood pressure; 
hypertension; masked hypertension; population science; prehyperten-
sion; risk stratification.
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Risk Stratification by CBP and ABP
The relationship between cardiovascular outcome and blood 
pressure (BP) is log linear, without a critical level above 
which the risk suddenly increases.1 However, for the diagno-
sis and management of hypertension, clinicians need opera-
tional thresholds.2,3 Therefore, the Joint National Committee 
on the Prevention, Detection, Evaluation and Treatment 
of High Blood Pressure (JNC7)2 and the World Health 
Organization and the International Society of Hypertension 
(WHO–ISH)3 proposed a classification of blood pressure 
based on conventional measurement into normal, prehyper-
tensive, and hypertensive levels.
Ambulatory blood pressure (ABP) monitoring substan-
tially refines the risk stratification in hypertensive patients4 
and in people randomly recruited from populations.5,6 
Few studies7–10 have examined whether ABP measurement 
refines risk stratification to a similar extent within each of 
the categories of office blood pressure. However, these stud-
ies had a sample size that ranged from 5919 to 942,8 most 
included selected patients,7–10 and all but 19 had as outcome 
variables intermediary outcomes, such as left ventricu-
lar mass,7 pulse wave velocity,8 and carotid intima-media 
thickness.10 To our knowledge, no previous studies have 
addressed risk stratification by ABP monitoring in large 
population cohorts across all categories of the conven-
tional blood pressure (CBP) using hard fatal and nonfatal 
outcomes. To resolve this research question, we analyzed 
7,826 untreated participants randomly recruited from 11 
populations and enrolled in the International Database on 
Ambulatory blood pressure in relation to Cardiovascular 
Outcomes (IDACO).11
METHODS
Study population
At the time of writing this article, the IDACO database11 
included 11 randomly recruited population cohorts12–20 and 
12,148 participants with available data on conventional and 
ABP. Details on recruitment of the IDACO cohorts are given 
in Supplementary Table  1. We excluded 4,322 participants 
because they were aged <18 years (n = 303), their CBP was 
not within the database (n  =  248), their nighttime blood 
pressure had not been recorded (n = 1,36714), they were tak-
ing antihypertensive drugs at baseline (n = 2,156), or their 
ABP recordings did not comply with recommended21 and 
predefined11 quality standards and covered fewer than 20 
hours or included fewer than 10  daytime or 5 nighttime 
readings (n = 248). Thus, the total number of participants 
included in the present analysis totaled 7,826.
Blood pressure measurement
Methods used for conventional and ABP measurement are 
described in detail in the Expanded Methods section. CBP 
was the average of 2 consecutive readings obtained either at 
the person’s home14,16–19 or at an examination center.13,15,20,22 
Portable monitors were programmed to obtain ABP read-
ings at 30-minute intervals throughout the whole day13,20 or 
at intervals ranging from 15 minutes22 to 30 minutes15 during 
the daytime and from 30 minutes22 to 60 minutes15 at night.
We categorized CBP according to the JNC72 and WHO–
ISH3 guidelines. Normal blood pressure was a level <120 mm 
Hg systolic and 80 mm Hg diastolic. Prehypertension encom-
passed 120–139 mm Hg systolic or 80–89 mm Hg diastolic. 
Patients who had a blood pressure of at least 140 mm Hg 
systolic or 90 mm Hg diastolic were classified as hyperten-
sive. To categorize levels of ABP, we followed the guidelines 
of the European Societies of Cardiology and Hypertension.23 
Ambulatory hypertension was a 24-hour level of 130 mm 
Hg systolic or 80 mm Hg diastolic or more; for the day-
time blood pressure, these thresholds were 135 mm Hg and 
85 mm Hg, and for the nighttime blood pressure they were 
120 mm Hg and 70 mm Hg, respectively. Sustained normo-
tension and hypertension were a normal blood pressure or 
hypertension on both conventional and ambulatory meas-
urement. Masked hypertension was ambulatory hyperten-
sion in participants with a normal CBP.
Other measurements
We used the questionnaires originally administered in 
each cohort to obtain information on each participant’s 
medical history and smoking and drinking habits. Body 
mass index was measured as body weight, in kilograms, 
divided by height, in meters squared. We measured serum 
cholesterol and blood glucose by automated enzymatic 
methods. Diabetes mellitus was the use of antidiabetic 
drugs, a fasting blood glucose concentration of at least 
7.0  mmol/L,13–16,18,19,22 a random blood glucose concentra-
tion of at least 11.1  mmol/L,13,14,17 a self-reported diagno-
sis,14,16,17 or diabetes documented in practice or hospital 
records.16
Ascertainment of events
We ascertained vital status and the incidence of fatal 
and nonfatal diseases from the appropriate sources in each 
country, as described in previous publications.24–26 Fatal and 
nonfatal stroke did not include transient ischemic attacks. 
Coronary events encompassed death from ischemic heart 
disease, sudden death, nonfatal myocardial infarction, and 
coronary revascularization. Cardiac events comprised cor-
onary endpoints and fatal and nonfatal heart failure. The 
composite cardiovascular endpoint included all aforemen-
tioned endpoints plus cardiovascular mortality. In all out-
come analyses, we only considered the first event within 
each category.
Statistical analysis
For database management and statistical analysis, we 
used SAS software, version 9.3 (SAS Institute, Cary, NC). 
For comparison of means and proportions, we applied the 
large-sample z test and the χ2 statistic, respectively. In Cox 
regression, we adjusted for cohort, sex, age, body mass index, 
smoking and drinking, serum cholesterol, history of cardio-
vascular complications, and diabetes mellitus. To adjust for 
cohort, we pooled participants recruited in the framework 
of the European Project on Genes in Hypertension (Kraków, 
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Novosibirsk, Padova, and Pilsen).19 We ascertained that the 
proportional hazard assumption underlying the Cox regres-
sion models was fulfilled by testing the interaction between 
the blood pressure categories and follow-up time. For cat-
egorical analyses, we presented hazard ratios (HRs) as float-
ing absolute risks and calculated their standard errors as 
described by Easton and colleagues.27 This approach allows 
calculation of a 95% confidence interval (CI) for the relative 
risk in the reference group.27 We compared HRs between 
groups by testing the significance of the appropriated inter-
action term. Statistical significance was an α level of <0.05 
on 2-sided tests.
RESULTS
Baseline characteristics
The study population consisted of 5,488 Europeans (70.1%), 
1,150 Asians (14.7%), and 1,188 South Americans (15.2%). 
The 7,826 participants included 3,706 women (47.4%). Mean 
(± standard deviation (SD)) age was 49.9 ± 15.6  years. At 
enrollment, 2,367 participants (30.2%) were smokers and 
3,941 (50.4%) reported intake of alcohol. In the whole study 
population, CBP averaged (± SD) 126.8 ± 18.7 mm Hg sys-
tolic and 78.3 ± 11.0 mm Hg diastolic. The median number of 
readings averaged to estimate the 24-hour blood pressure was 
52 (5th to 95th percentile interval, 35–81; range, 20–99); the 
24-hour ABPs were 121.7 ± 13.3 mm Hg and 73.0 ± 8.1 mm 
Hg, respectively. These levels were 128.2 ± 14.4 mm Hg and 
78.3 ± 8.8 mm Hg during daytime and 110.3 ± 13.8 mm Hg 
and 63.7 ± 8.7 mm Hg at night.
On CBP measurement, according to the JNC72/WHO–
ISH3 criteria, 2,639 (33.7%), 3,076 (39.3%), and 2,111 
(27.0%) participants were normotensive, prehypertensive, 
or hypertensive, respectively. Table 1 lists the characteristics 
of the study participants by these categories. Using conven-
tional and daytime ABP measurement for cross-classifica-
tion, the prevalence of masked hypertension was higher 
(P  <  0.0001) among prehypertensive patients (n  =  900; 
29.3%) than those with normotension (n  =  198; 7.5%). 
Supplementary Tables 1 and 2 and the Supplementary 
Results provide detailed information on the determinants 
of masked hypertension and their discriminative power in 
our untreated participants.
Incidence of events
In the overall study population, the median follow-up was 
11.3 years (5th to 95th percentile interval, 2.6–18.2 years). 
Across centers, median follow-up ranged from 2.5 years (5th 
to 95th percentile interval, 2.3–2.6) in Jingning, China, to 
17.8 years (16.6–18.2 years) in Dublin, Ireland. During 87,624 
person-years of follow-up, 809 participants died (9.2/1,000 
person-years) and 639 experienced a fatal or nonfatal cardi-
ovascular complication (7.5/1,000 person-years). Mortality 
included 276 cardiovascular and 503 noncardiovascular 
deaths, 23 deaths from unknown causes, and 7 deaths due to 
renal failure. Considering cause-specific first cardiovascular 
events, the incidence of fatal and nonfatal stroke was 42 and 
183, respectively. Cardiac events consisted of 39 fatal and 
134 nonfatal cases of acute myocardial infarction, 45 deaths 
from ischemic heart diseases, 6 sudden deaths, 16 fatal and 
96 nonfatal cases of heart failure, and 47 cases of surgical or 
percutaneous coronary revascularization.
Risk associated with categories of CBP
In the first step of our analyses, we assessed, as as inter-
nal validation of our dataset, whether as-expected risks 
increased across increasing categories of CBP. Rates of mor-
tality and fatality combined with nonfatal events increased 
(P < 0.0001) with higher categories of CBP (Table 2). With 
normotension as the reference (Table  2), prehypertensive 
participants had a significantly higher risk of a composite 
cardiovascular endpoint (+41%; P = 0.01) and stroke (+92%; 
P = 0.02). With hypertension as the reference (Table 2), the 
risks of cardiovascular death (–28%; P  =  0.01), a compos-
ite cardiovascular endpoint (–34%; P  <  0.0001), a cardiac 
(–33%; P = 0.0007) or coronary (‒27%; P = 0.02) event, or 
stroke (–47%; P < 0.0001) were significantly lower in prehy-
pertensive participants.
Risks associated with ABP by categories of CBP
In the next step of our analyses, we assessed whether the 
ABP level measured on a continuous scale differentially con-
tributed to risk stratification across increasing categories of 
the CBP. We expressed HRs for 5-mm Hg and 10-mm Hg 
increments in the ambulatory diastolic and systolic blood 
pressures, respectively.
Mortality. In multivariable-adjusted analyses, taking 
normotension as the reference, the HRs for total and car-
diovascular mortality associated with diastolic (+5 mm 
Hg; Supplementary Table  3) and systolic (+10 mm Hg; 
Supplementary Table  4) blood pressures as measured by 
24-hour daytime and nighttime monitoring did not differ 
significantly (P ≥ 0.13) from those in prehypertensive and 
hypertensive participants. The only exception was the higher 
HR for total mortality in relation to daytime diastolic blood 
pressure (DBP) in hypertensive compared with normoten-
sive participants (1.10 vs. 0.92; P = 0.04).
Fatal combined with nonfatal endpoints.  In multivar-
iable-adjusted analyses, taking normotension as the refer-
ence, the HRs for the composite cardiovascular endpoint 
and cardiac events associated with diastolic (Table  3) and 
systolic (Table  4) blood pressures as measured by 24-hour 
daytime and nighttime monitoring did not significantly dif-
fer (P ≥ 0.19) from those in prehypertensive and hyperten-
sive participants. However, the HRs for stroke associated 
with 24-hour and daytime DBPs were significantly (0.005 ≤ 
P ≤ 0.04) higher in normotensive participants than in prehy-
pertensive and hypertensive participants. The estimates for 
24-hour DBP were 1.98 vs.1.19 vs.1.28 and for the daytime 
DBP were 1.73 vs.1.09 vs.1.24, respectively (Table 3). A simi-
lar trend (0.04 ≤ P ≤ 0.11) was observed for stroke in relation 
to the 24-hour and daytime systolic blood pressures (SBPs; 
Table  4). The estimates for 24-hour SBP were 2.27 vs.1.39 
vs.1.38 and for daytime SBP were 2.07 vs.1.20 vs.1.37.
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Risk associated with masked hypertension
In the last step of our analyses, with sustained normo-
tension as the reference (Figure  1), we first explored the 
HRs for the composite cardiovascular endpoint and stroke 
associated with masked hypertension, as defined on the 
basis of the daytime ABP. Among participants with nor-
motension, 198 (7.5%) had masked hypertension because 
of an elevated daytime systolic (98 (49.5%)) or diastolic 63 
(31.8%)) blood pressure or both (37 (18.7%)). Among par-
ticipants with prehypertension, 900 (29.3%) had masked 
hypertension, because of an elevated daytime systolic (391 
(43.4%)) or diastolic (216 (24.0%)) blood pressure or both 
(293 (32.6%)). Compared with true normotension, the 
HRs associated with masked hypertension in normoten-
sive participants were 2.11 (95% CI, 1.24–3.60; P = 0.006) 
for a composite cardiovascular endpoint and 3.02 (95% 
CI, 1.25–7.32; P = 0.01) for stroke. The corresponding HRs 
associated with masked hypertension in prehypertensive 
participants were 2.08 (95% CI, 1.67–2.59; P  <  0.0001) 
and 2.97 (95% CI, 2.03–4.35; P < 0.0001), respectively. The 
HRs associated with masked hypertension compared with 
true normotension were similar among normotensive and 
prehypertensive participants (P ≥ 0.75). Compared with 
prehypertension without masked hypertension, the HRs 
associated with masked hypertension in prehypertensive 
participants were 1.53 (95% CI, 1.23–1.91; P = 0.0001) for 
the composite cardiovascular endpoint and 1.48 (95% CI, 
1.01–2.16; P = 0.04) for stroke (Figure 1).
As shown in the Supplementary Results, the above find-
ings were consistent if we defined masked hypertension 
based on the 24-hour (Supplementary Figure 1) or nighttime 
(Supplementary Figure 2) blood pressures.
Table 1. Baseline characteristics by category of conventional blood pressure
Characteristic Normotension Prehypertension Hypertension
Number (%)
All participants in category 2,639 (33.7) 3,076 (39.3) 2,111 (27.0)
 European 1,765 (66.9) 2,156 (70.1)† 1,567 (74.2)†
 Asian 381 (14.4) 535 (17.4)† 234 (11.1)‡
 South American 493 (18.7) 385 (12.5)‡ 310 (14.7)*
 Women 1,676 (63.5) 1,328 (43.2)‡ 702 (33.3)‡
 Smokers 875 (33.2) 947 (30.1) 545 (25.9)‡
 Drinking alcohol 1,172 (45.0) 1,572 (53.6)‡ 1,197 (62.7)‡
 Diabetes mellitus 73 (2.8) 156 (5.1)‡ 140 (6.6)‡
 Cardiovascular disorder 96 (3.6) 162 (5.1)‡ 145 (6.9)*
 Daytime hypertension 198 (7.5) 900 (29.2)‡ 1,525 (72.2)‡
Mean ± standard deviation
Age, years 42.2 ± 13.8 50.2 ± 15.3‡ 59.0 ± 13.1‡
Body mass index, kg/m2 23.5 ± 3.4 25.3 ± 4.0‡ 26.6 ± 4.2‡
Conventional pressure (mm Hg)
 Systolic 108.6 ± 7.3 126.4 ± 7.0‡ 150.0 ± 14.4‡
 Diastolic 69.0 ± 6.3 78.3 ± 6.8‡ 89.7 ± 9.7‡
Ambulatory pressure (mm Hg)
 24-hour systolic 112.6 ± 8.5 121.1 ± 9.3‡ 133.9 ± 13.5‡
 24-hour diastolic 68.3 ± 5.6 72.9 ± 6.4‡ 79.1 ± 8.7‡
 Daytime systolic 118.5 ± 9.8 127.8 ± 10.5‡ 141.0 ± 14.3‡
 Daytime diastolic 73.4 ± 6.4 78.2 ± 7.3‡ 84.6 ± 9.6‡
 Nighttime systolic 102.5 ± 9.3 109.6 ± 10.7‡ 121.0 ± 15.6‡
 Nighttime diastolic 59.3 ± 6.5 63.5 ± 7.4‡ 69.4 ± 9.6‡
Blood glucose, mmol/L 4.8 ± 0.9 5.1 ± 1.1‡ 5.4 ± 1.4‡
Serum cholesterol, mmol/L 5.3 ± 1.1 5.6 ± 1.2‡ 5.9 ± 1.2‡
Thresholds for the conventional blood pressure were <120/<80 mm Hg for normotension, 120–139/80–89 mm Hg for prehypertension, and 
≥140/≥90 mm Hg for hypertension. Daytime hypertension was an ambulatory blood pressure of ≥135/≥85 mm Hg. To convert glucose and 
cholesterol from mmol/l to mg/dl, multiply by 18.01 and 38.61, respectively. Significance of the difference with the adjacent column as follows: 
* P ≤ 0.05, † P ≤ 0.01, and ‡ P ≤ 0.001.
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Sensitivity analyses
The incidence of endpoints differed among IDACO 
cohorts according to ethnicity, sex ratio, and age distri-
bution. However, our results, which describe the risk of 
stroke associated with 24-hour (Supplementary Tables 6 
and 8) or daytime (Supplementary Tables 7 and 9) DBP, 
remained consistent when we excluded 1 cohort at a time 
(Supplementary Tables 6 and 7) or in analyses stratified by 
sex, age (<60 vs. ≥60  years), or ethnicity (Supplementary 
Tables 8 and 9).
Table 2. Risk associated with prehypertension vs. normotension or hypertension
Endpoint
Number of endpoints  
(rate per 1,000 person-years)
Hazard ratios (confidence interval)  
associated with prehypertension
NT PHT HT vs. NT P vs. HT P
Mortality
 Total 126 (4.1) 313 (9.0) 370 (16.6) 1.18 (0.96–1.46) 0.12 0.86 (0.73–1.00) 0.050
 Cardiovascular 31 (1.0) 97 (2.8) 148 (6.7) 1.37 (0.91–2.07) 0.13 0.72 (0.55–0.94) 0.012
 Noncardiovascular 87 (2.8) 207 (6.0) 209 (9.4) 1.17 (0.90–1.51) 0.24 0.98 (0.80–1.20) 0.84
Fatal plus nonfatal events
 All cardiovascular 77 (2.5) 219 (6.5) 343 (16.1) 1.41 (1.08–1.84) 0.012 0.66 (0.55–0.78) <0.0001
 Cardiac 50 (1.6) 128 (3.7) 205 (9.5) 1.30 (0.93–1.83) 0.12 0.67 (0.54–0.85) 0.0007
 Coronary 40 (1.3) 98 (2.9) 145 (6.6) 1.25 (0.86–1.82) 0.25 0.73 (0.56–0.95) 0.020
 Stroke 18 (0.6) 76 (2.2) 131 (6.0) 1.92 (1.14–3.24) 0.015 0.53 (0.40–0.72) <0.0001
Abbreviations: HT, hypertension on conventional blood pressure measurement; NT, normotension on conventional blood pressure measure-
ment; PHT, prehypertension on conventional blood pressure measurement.
NT (<120/<80 mm Hg), PHT (120–139/80–89 mm Hg), and HT (≥140/≥90 mm Hg) were defined according to the JNC72/WHO-ISH3 criteria. 
All rates increased from NT to PHT and from PHT to HT (P < 0.0001). Hazard ratios, presented with 95% confidence interval, express the risk 
compared with prehypertension. All Cox models were adjusted for cohort, sex, age, body mass index, smoking and drinking, serum cholesterol, 
history of cardiovascular complications, and diabetes mellitus.
Table 3. Multivariable-adjusted hazard ratios for cardiovascular events associated with diastolic ambulatory pressure by category of 
conventional blood pressure
Endpoint by subgroup
24-hour Daytime Nighttime
HR (CI) P HR (CI) P HR (CI) P
All cardiovascular events
 Normotension 1.32 (1.09–1.60)† … 1.26 (1.06–1.49)† … 1.18 (1.00–1.38)* …
 Prehypertension 1.16 (1.04–1.29)† 0.19 1.12 (1.02–1.23)* 0.20 1.10 (1.01–1.21)* 0.37
 Hypertension 1.20 (1.12–1.27)§ 0.37 1.15 (1.08–1.22)§ 0.43 1.15 (1.09–1.21)§ 0.67
Cardiac events
 Normotension 1.10 (0.84–1.43) … 1.10 (0.87–1.38) 1.04 (0.83–1.29) …
 Prehypertension 1.15 (0.99–1.32) 0.93 1.14 (1.00–1.29)* 0.87 1.04 (0.92–1.17) 0.79
 Hypertension 1.14 (1.05–1.24)† 0.84 1.10 (1.02–1.18)* 0.83 1.10 (1.03–1.18)† 0.89
Stroke
 Normotension 1.98 (1.44–2.74)§ … 1.73 (1.29–2.32)‡ … 1.61 (1.18–2.20)† …
 Prehypertension 1.19 (0.99–1.43) 0.005 1.09 (0.93–1.27) 0.005 1.21 (1.04–1.40)* 0.12
 Hypertension 1.28 (1.16–1.41)§ 0.016 1.24 (1.13–1.35)§ 0.045 1.20 (1.10–1.31)§ 0.13
Normotension (<120/<80 mm Hg), prehypertension (120–139/80–89 mm Hg), and hypertension (≥140/≥90 mm Hg) refer to the classification 
based on the conventional blood pressure according to the JNC72/WHO-ISH3 criteria. The number of participants and cardiovascular events 
per group appear in Table 2. HRs, given with 95% CI, express the risk for a 5-mm Hg increase in diastolic blood pressure and were adjusted 
for cohort, sex, age, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular complications, and diabetes mellitus. 
P values are for the comparison of the HRs in prehypertensive and hypertensive participants with the HRs in normotensive participants. The 
differences in the HRs between prehypertensive and hypertensive participants were all nonsignificant (P ≥ 0.074).
Significance of the HRs: * P ≤ 0.05; † P ≤ 0.01, ‡ P ≤ 0.001, and § P ≤ 0.0001.
Abbreviations: CI, confidence interval; HR, hazard ratio; ..., not applicable.
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DISCUSSION
Our current metaanalyses of patient-level data included 
7,826 people not treated with blood pressure–lowering drugs. 
They were randomly recruited from 11 populations, and their 
follow-up covered, on average, 11.3  years. The key finding 
was that the relative risks associated with a higher ABP were 
similar across the 3 categories of the CBP for all endpoints 
under study with the exception of stroke. In normotensive 
and prehypertensive people with masked hypertension, the 
risk of cardiovascular events and stroke approximately dou-
bled with each 10-mm Hg systolic or 5-mm Hg diastolic 
increase in ABP. We recently confirmed these findings in a 
patient-level metaanalysis of the International Database on 
Home blood pressure in relation to Cardiovascular Outcome 
using self-measured home blood pressure instead of ABP as 
the technique to assess the out-of-the-office blood pressure.28 
The replication of our current findings lends strong support 
Table 4. Multivariable-adjusted hazard ratios for cardiovascular events associated with systolic ambulatory pressure by category of 
conventional blood pressure
Endpoint by subgroup
24-hour Daytime Nighttime
HR (CI) P HR (CI) P HR (CI) P
All cardiovascular events
 Normotension 1.51 (1.19–1.92)‡ … 1.44 (1.16–1.80)† … 1.30 (1.07–1.59)† …
 Prehypertension 1.27 (1.10–1.45)† 0.47 1.17 (1.03–1.32)* 0.41 1.17 (1.05–1.31)† 0.42
 Hypertension 1.26 (1.18–1.35)§ 0.44 1.24 (1.16–1.33)§ 0.68 1.17 (1.11–1.24)§ 0.36
Cardiac events
 Normotension 1.19 (0.85–1.68) … 1.15 (0.84–1.57) … 1.12 (0.84–1.48) …
 Prehypertension 1.16 (0.96–1.41) 0.68 1.11 (0.93–1.32) 0.49 1.04 (0.89–1.22) 0.66
 Hypertension 1.21 (1.10–1.32)§ 0.66 1.18 (1.07–1.29)‡ 0.41 1.14 (1.06–1.23)‡ 0.99
Stroke
 Normotension 2.27 (1.43–3.62)‡ … 2.07 (1.36–3.15)‡ … 1.66 (1.13–2.43)* …
 Prehypertension 1.39 (1.12–1.73)† 0.11 1.20 (0.99–1.46) 0.035 1.34 (1.13–1.59)‡ 0.44
 Hypertension 1.38 (1.24–1.53)§ 0.071 1.37 (1.23–1.52)§ 0.099 1.22 (1.12–1.32)§ 0.16
Normotension (<120/<80 mm Hg), prehypertension (120–139/80–89 mm Hg), and hypertension (≥140/≥90 mm Hg) refer to the JNC clas-
sification based on the conventional blood pressure according to the JNC72/WHO-ISH3 criteria. The number of participants and cardiovascular 
events per group appear in Table 2. HRs, given with 95% CI, express the risk for a 10-mm Hg increase in systolic blood pressure and were 
adjusted for cohort, sex, age, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular complications, and diabetes 
mellitus. P values are for the comparison of the HRs in prehypertensive and hypertensive participants with the HRs in normotensive participants. 
The differences in the HRs between prehypertensive and hypertensive participants were all nonsignificant (P ≥ 0.22).
Significance of the HRs: * P ≤ 0.05; † P ≤ 0.01, ‡ P ≤ 0.001, and § P ≤ 0.0001.
Abbreviations: CI, confidence interval; HR, hazard ratio; ..., not applicable.
Figure 1. Hazard ratios for cardiovascular events and stroke associated with masked hypertension on daytime blood pressure monitoring in partici-
pants with normotension or prehypertension. Participants with sustained normotension are the reference group. Normotension (<120/<80 mm Hg) and 
prehypertension (120–139/80–89 mm Hg) refer to the classification based on the conventional blood pressure according to the JNC72/WHO-ISH3 criteria. 
Thresholds for daytime hypertension were ≥135 mm Hg systolic or ≥85 mm Hg diastolic. The hazard ratios (HRs) were adjusted for cohort, sex, age, body 
mass index, smoking and drinking, serum cholesterol, history of cardiovascular complications, and diabetes mellitus. Horizontal lines denote the 95% 
confidence interval (CI). Compared with prehypertension without masked hypertension, the HRs associated with masked hypertension in prehyperten-
sive patients were 1.53 (95% CI, 1.23–1.91; P = 0.0001) for the composite cardiovascular endpoint and 1.48 (95% CI, 1.01–2.16; P = 0.04) for stroke.
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to the concept that out-of-the-office blood pressure meas-
urement should be applied in normotensive or prehyperten-
sive people with suspected masked hypertension to screen 
for this high-risk condition. Using the daytime ABP, in our 
current study, out-of-the-office blood pressure unmasked 
masked hypertension in 7.5% and 29.3% of participants 
with normotension or prehypertension on CBP, respectively. 
However, in the absence of any trial evidence, one can only 
speculate about the number of events that can be prevented 
by the early treatment of this condition.
Few other studies7–10 have addressed the association 
between health outcomes and the ABP across categories of 
the CBP, as proposed by US2 and international3 guidelines. 
Most studies were only cross-sectional7,8,10 or focused only 
on intermediate signs of target organ damage.7,8,10 Zhu and 
colleagues studied 532 white and 410 black twins (mean age, 
17.6 years). For youth aged <18 years, prehypertension was a 
CBP >120 mm Hg systolic or 80 mm Hg diastolic or ranging 
from the 90th to the 95th percentile after stratification for 
sex, age, and height;29 for participants aged ≥18 years, prehy-
pertension was a blood pressure of 120–139 mm Hg systolic 
or 80–89 mm Hg diastolic.2,3 The prevalence of prehyper-
tension was 12.0%. Cardiovascular risk factors, including 
obesity and high pulse wave velocity, clustered in prehyper-
tensive participants.8
Manios and coworkers10 enrolled 807 referred patients 
whose office blood pressure was <140 mm Hg systolic and 
90 mm Hg diastolic. They applied the same criteria as we did 
to categorize their participants. The prevalence of pure pre-
hypertension and prehypertension with masked hyperten-
sion was 59.9% and 19.7%, respectively. With adjustments 
applied, prehypertensive patients with masked hypertension 
had higher (P < 0.01) carotid intima-media thickness than 
prehypertensive patients without masked hypertension and 
normotensive patients (712 vs. 649 vs. 655  µm). Shimbo 
and colleagues7 studied 813 untreated participants recruited 
from a worksite-based population study and obtained 9 
blood pressure readings (3 at each of 3 visits over 3 weeks). 
Among 482 normotensive (<120/<80 mm Hg) and 287 pre-
hypertensive (120–139/80–85 mm Hg) participants, the 
prevalence of masked hypertension was 3.9% and 34.1%, 
respectively. In multivariable-adjusted models, participants 
with prehypertension or masked hypertension (awake blood 
pressure ≥135/≥85 mm Hg) had greater left ventricular 
mass index than those with normotension (60.8 vs. 64.2 g/
m2; P < 0.01), but left ventricular mass index was not dif-
ferent among prehypertensive participants without and with 
masked hypertension (66.1 vs. 68.6 g/m2; P = 0.19).
Pierdomenico and colleagues9 completed the only study 
that also investigated the incidence of cardiovascular events 
in prehypertensive patients with (n  =  120) and without 
(n  =  471) masked hypertension. The participants were 
hospital staff, patients referred for reasons other than car-
diovascular disease or hypertension, and volunteers. During 
6.6 years of follow-up (range, 0.5–15.5 years), 29 fatal and 
nonfatal cardiovascular events occurred. In prehypertensive 
patients without and with masked hypertension, the event 
rates per 100 patient-years were 0.57 and 1.51, respectively. 
With adjustments applied for covariables, including the 
CBP, Cox regression showed that cardiovascular risk was 
significantly higher in masked hypertension than in true 
prehypertension (masked vs. true prehypertension, relative 
risk 2.65; 95% CI, 1.18–5.98; P  =  0.018). Prehypertension 
and masked hypertension carry great risk to develop into 
hypertension. In the Flemish Study on Environment, Genes 
and Health Outcomes,30 the 4-year progression rates from 
prehypertension to hypertension were 17.9% and 26.3% 
in participants aged <50  years and those aged ≥50  years, 
respectively. In the Copenhagen Monitoring of Trends and 
Determinants in Cardiovascular Disease,31 the progression 
rate over 10 years was 37.3%. In multivariable-adjusted anal-
yses, progression to prehypertension or to hypertension was 
associated with 10-year cardiovascular risks of 11.1% and 
13.9%, respectively.31
We5,32 and other investigators33–35 demonstrated that 
masked hypertension carries a risk approaching that of 
sustained hypertension. However, the novel finding of our 
current study is that ABP monitoring contributes to risk 
stratification in people who, on the basis of their CBP, would 
be categorized as being at low cardiovascular risk and that 
masked hypertension is the driver of this risk. The present 
findings therefore suggest that screening for masked hyper-
tension among prehypertensive and even normotensive 
people might be useful. The relationship between the cardio-
vascular and renal complications driven by blood pressure 
is continuous, at least down to a CBP level of 115 mm Hg 
systolic or 75 mm Hg diastolic.1 Stroke is the complication of 
hypertension most closely associated with blood pressure.36 
The continuous nature of the relation with blood pressure 
not only holds true in hypertensive patients but in normo-
tensive people as well.1,37 Our current findings clearly show 
that the relative risk of stroke increases with the ABP in nor-
motensive people at twice the rate observed in patients with 
hypertension. In addition, we demonstrated that masked 
hypertension in normotensive and prehypertensive patients 
contributes to the risk of stroke and cardiovascular compli-
cations. Our current findings suggest that ABP monitoring 
might be indicated in normotensive and prehypertensive 
people to screen for masked hypertension, a condition that 
confers a risk approaching that of sustained hypertension.5 
Our current data and the literature show that men, prehy-
pertensive patients, diabetic patients,32 smokers,38 alco-
hol consumers, and individuals with increased cholesterol 
(≥5.7 mmol/L) are at increased risk of having masked hyper-
tension. However, robust evidence for the routine imple-
mentation of ABP monitoring as a screening tool for masked 
hypertension should come from randomized clinical trials 
that prove that the early diagnosis of masked hypertension 
and treatment of this condition reduces the incidence of car-
diovascular events.
The strong points of our current study are the use of 
ambulatory monitoring to assess blood pressure; the rela-
tively large sample size, representing populations from 
Europe, Asia, and South America; and the removal of treated 
participants from the analysis. Nevertheless, our study also 
has limitations. First, the number of strokes was relatively 
low, so that estimates of stroke risk might be less precise than 
wished for. We could not differentiate between ischemic and 
hemorrhagic stroke. On the other hand, the probability of 
detecting a relation with a predictor variable increases with 
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the number of events. Thus, that we could already detect a 
statistically significant difference between normotensive and 
hypertensive participants in the HRs for stroke associated 
with the ABP might reflect a true and very strong under-
lying relation in normotensive people. Second, we did not 
determine the reproducibility of masked hypertension in 
the context of our current population study. However, Viera 
and colleagues reported prevalence rates of masked hyper-
tension among untreated patients with a borderline elevated 
office blood pressure to be 54% and 53% on first and repeat 
assessment with an agreement of 73%.39 Among patients 
who underwent repeat ambulatory monitoring for a medical 
indication, Ben-Dov and coworkers reported an agreement 
of 72%.40 Third, most participants had their CBP measured 
while seated at an examination center. By contrast, in other 
cohorts the CBP was measured in the supine position15 or 
at home.14,17–19 Fourth, ABP monitoring was not standard-
ized in terms of device type and intervals between successive 
readings, but the same SAS macro ensured that daytime was 
always defined in the same fashion, using short fixed clock-
time intervals,41 and that the time-weighted means were 
calculated identically across cohorts. Finally, binning a con-
tinuous variable such as the CBP is deemed to lose informa-
tion.42 However, we followed the categorization proposed by 
guidelines2,3 for use in clinical practice and to be indiscrimi-
nately applied to adults of both sexes across the age range.
In conclusion, ABP monitoring contributes to risk strati-
fication in normotension and prehypertension, particularly 
in the presence of masked hypertension. Further research 
should address the question whether ABP monitoring might 
be a cost-effective screening technique to prevent the cardio-
vascular complications associated with masked hypertension 
in patients with prehypertension23 or even in normotensive 
people in whom unexplained target organ damage is pre-
sent or who accumulate characteristics often associated with 
masked hypertension (Supplementary Results).
SUPPLEMENTARY MATERIAL
Supplementary materials are available at American Journal 
of Hypertension (http://ajh.oxfordjournals.org).
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EXPANDED METHODS   
Study population   
As described in detail elsewhere,1 we constructed the International Database on Ambulatory 
blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO).  Studies were 
eligible for inclusion, if they involved a random population sample, if baseline information on 
the ambulatory blood pressure and cardiovascular risk factors was available, and if the sub-
sequent follow-up included both fatal and nonfatal outcomes.  Details on the recruitment of 
participants appear in Table S1 and on the quality of the ambulatory blood pressure record-
ings in the Supplementary Materials associated with a recent IDACO publication.2   
In the current study, analyzed participants were 1823 residents from Copenhagen, Den-
mark;3 851 inhabitants from Ohasama, Japan;4 1175 subjects from Noorderkempen, Bel-
gium;5 713 older men from Uppsala, Sweden;6 1188 subjects from Montevideo, Uruguay;7 
299 villagers from the Jingning County, China;8 204 subjects from Novosibirsk, the Russian 
Federation;9 133 from Pilsen, Czech Republic;10 930 from Dublin, Ireland;11 266 from Pad-
ua, Italy;10 and 244 from Kraków, Poland.10  All participants gave informed written consent.  
Subjects recruited in Kraków, Novosibirsk, Pilsen, and Padova took part in the European 
Project on Genes in Hypertension (EPOGH).10  All participants gave informed written con-
sent.   
Blood pressure measurement   
Conventional blood pressure was measured by trained observers with a mercury sphygmo-
manometer,8,10-12 with validated auscultatory4 (USM-700F, UEDA Electronic Works, Tokyo, 
Japan) or oscillometric7 (OMRON HEM-705CP, Omron Corporation, Tokyo, Japan) devices, 
using the appropriate cuff size, with participants in the sitting4,5,7-12 or supine6 position.  
Conventional blood pressure was the average of two consecutive readings obtained either at 
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the person’s home5,7-10 or at an examination center.4,6,11,12  We programmed portable 
monitors to obtain ambulatory blood pressure readings at 30–minute intervals throughout the 
whole day,4,11 or at intervals ranging from 15minutes12 to 30 minutes6 during daytime and 
from 30 minutes12 to 60 minutes6 at night.  The devices implemented an auscultatory algo-
rithm (Accutracker II) in Uppsala6 or an oscillometric technique (SpaceLabs 90202 and 
90207, Nippon Colin, and  ABPM 630) in the other cohorts.4-11   
The same SAS macro processed all ambulatory recordings, which generally remained 
unedited.  The Ohasama recordings were edited sparsely according to previously published 
criteria.13  Within individual subjects, we weighted the means of the ambulatory blood pres-
sure by the interval between readings.  When accounting for the daily pattern of activities of 
the participants, we defined daytime as the interval ranging from 1000 h to 2000 h in people 
from Europe5,6,9-12 and South America,7 and from 0800 h to 1800 h in Asians.4,8  The cor-
responding nighttime intervals ranged from midnight to 0600 h5-7,9-12  and from 2200 h to 
0400 h.4,8  These fixed time intervals eliminate the transition periods in the morning and 
evening when blood pressure changes rapidly, resulting in daytime and nighttime blood 
pressure levels that are within 1–2 mm Hg of the awake and asleep levels.8,14    
We categorized conventional blood pressure according to the JNC715 and WHO-ISH16 
guidelines.  Normal blood pressure was a level lower than 120 mm Hg systolic and 
80 mm Hg diastolic.  High-normal blood pressure encompassed 120 to 139 mm Hg systolic 
or 80 to 89 mm Hg diastolic.  Patients who had a blood pressure of at least 140 mm Hg sys-
tolic or 90 mm Hg diastolic  were classified as hypertensive.  To categorize levels of the am-
bulatory blood pressure, we followed the guidelines of the European Societies of Cardiology 
and Hypertension.17  Ambulatory hypertension was a 24-h level of at least 130 mm Hg sys-
tolic or 80 mm Hg diastolic; for the daytime blood pressure these thresholds were 
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135 mm Hg and 85 mm Hg, and for the nighttime blood pressure 120 mm Hg and 70 mm Hg, 
respectively.   
Correlates of masked hypertension  
Based on previous research,18 we evaluated sex, age, body mass index, the level of the 
conventionally measured systolic and diastolic blood pressure, current smoking and drinking, 
serum cholesterol, history of cardiovascular complications and diabetes mellitus as potential 
determinants of masked hypertension.  We modeled these variables using single and multi-
variable logistic regression.  We estimated the performance of variables to differentiate be-
tween individuals with and without masked hypertension, using sensitivity, specificity, the 
misclassification rate and the area under the receiver operating characteristic curve.  We 
applied Younden’s index to determine the optimal discrimination limit for continuous corre-
lates.   
The difference in the HRs associated with the ABP analyzed as a continuous variable be-
tween participants belonging to different CBP categories was tested by introducing the prod-
uct term between CBP category (binary variable) and ABP (continuous variable) along with 
the other covariables in models including the two group to be compared (normotension vs. 
prehypertension and prehypertension vs. hypertension). 
SUPPLEMENTARY RESULTS  
Correlates of masked hypertension   
 In both single (Table S1) and multiple (Table S2) logistic regression analysis, male sex, old-
er age, higher body mass index, serum cholesterol and higher conventional systolic and di-
astolic blood pressure, history of diabetes mellitus and current smoking and alcohol intake 
correlated with masked hypertension in participants with a conventional blood pressure be-
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low 140 mm Hg systolic and 90 mmHg diastolic.   Younden’s index the best cutoff points for 
the conventional blood pressure to distinguish between sustained normotension and masked 
hypertension were 120 mm Hg systolic and 77 mm Hg diastolic.  The area under the receiv-
er operating characteristic curve for all the above predictors combined was 0.76 for the 
model with dichotomized covariates and 0.77 for the model with continuous covariables, in-
dicating moderate discrimination between true normotension and normotension associated 
with masked hypertension.  
Risk of masked hypertension defined on the basis of 24-h or nighttime ambulatory 
blood pressure.   
When we defined masked hypertension on the basis of the 24-h blood pressure (Figure S1), 
112 (4.2%) and 672 (21.8%) of normotensive and prehypertensive participants had masked 
hypertension.  Compared to true normotension, the hazard ratios associated with 24-h 
masked hypertension in normotensive subjects, were 2.53 (CI, 1.35–4.74; P=0.004) for a 
composite cardiovascular endpoint and 4.12 (CI, 1.54–11.1; P = 0.005) for stroke.  The cor-
responding hazard ratios associated with 24-h masked hypertension in prehypertensive sub-
jects were in 2.18 (CI, 1.72–2.76; P<0.001) and 3.18 (CI, 2.13–4.75; P<0.0001), respective-
ly.  The hazard ratios associated with 24-h masked hypertension tended to be higher in nor-
motensive compared with prehypertensive subjects (P≤ 0.12).  Compared to  prehyperten-
sion without masked hypertension, the hazard ratios associated with masked hypertension in 
prehypertensive subjects were 1.61 (95% confidence interval, 1.27–2.04; P<0.0001) for the 
composite cardiovascular endpoint and 1.63 (1.09–2.42; P = 0.02) for stroke.   
Finally, we defined based on the nighttime blood pressure (Figure S2). 202 (7.6%) and 
752 (24.4%) of the normotensive and prehypertensive participants had masked hyperten-
sion.  Compared to true normotension, the hazard ratios associated with nighttime masked 
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hypertension in normotensive subjects, were 2.17 (CI, 1.31–3.62; P=0.003) for a composite 
cardiovascular endpoint and 3.35 (CI, 1.38–8.13; P=0.008) for stroke.  The corresponding 
hazard ratios associated with nighttime masked hypertension in prehypertensive subjects 
were 2.10 (CI, 1.66–2.65; P<0.0001) and 3.39 (CI, 2.36–4.89; P<0.0001), respectively.  The 
hazard ratios associated with nighttime masked hypertension compared with true normoten-
sion were similar among normotensive and prehypertensive subjects (P≥0.41).  Compared 
to  prehypertension without masked hypertension, the hazard ratios associated with masked 
hypertension in prehypertensive subjects, were 1.46 (95% confidence interval [CI], 1.18–
1.88; P = 0.0008) for the composite cardiovascular endpoint and 1.78 (CI, 1.24–2.56; P = 
0.002) for stroke.   
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Table S1  Recruitment of IDACO cohorts   
Catchment area  Sampling frame   
Starting point to  
recruit sample  
Participation 
rate (%)  
Nº in 
IDACO  
database  
Nooderkempen, Belgium  Family-based random sample  Address list  78  2542  
JingNing, Zhejiang, China  Family-based random sample  Villages, all inhabitants invited  62  360  
Pilsen, Czech Republic  Family-based random sample  Address list  82  174  
Copenhagen County, Denmark  Stratified random sample of women 
and men aged 30, 40, 50 and 60 years  
Population registry  83  2311  
Mirano (Venice), Torrebelvicino 
(Vicenza), Valli del Pasubio (Vi-
cenza), Italy  
Population-based sample of women 
and men ≥18 years  
Address list  73  310  
Ohasama, Iwate prefecture,  
Japan  
People aged ≥40 years  Address list  78  1535  
Niepolomice, Kràkow, Poland  Family-based random sample  Address list  54  321  
Octyabrsky district, Novosibirsk,  
Russian Federation  
Family-based random sample  Address list  68  250  
Montevideo, Uruguay  Age-stratified random sample  Members of a health insurance 
organization  
78  1859  
Uppsala, Sweden  Men aged ≥50 year  Population census  80  1143  
Allied Irish Bank Study  Bank employees working at branches 
across Ireland  
All invited  14  981  
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Table S2  Diagnostic accuracy of various predictors of masked hypertension in 5715 subjects who were  
normotensive or prehypertensive on conventional measurement   
Predictor  Odds ratio  P  Sensitivity  Specificity  
Misclassification 
rate  
Male sex   2.27 (1.98–2.60)  <0.0001  0.64 (0.61–0.67)  0.56 (0.55–0.58)  0.42 (0.41–0.44)  
Age ≥41 years  2.46 (2.10–2.88)  <0.0001  0.79 (0.77–0.82)  0.39 (0.38–0.41)  0.53 (0.52–0.54)  
Body mass index ≥25 kg/m2  2.01 (1.76–2.29)  <0.0001  0.53 (0.50–0.56)  0.64 (0.63–0.66)  0.38 (0.37–0.39)  
Systolic pressure ≥120 mm Hg  4.36 (3.76–5.06)  <0.0001  0.75 (0.73–0.78)  0.59 (0.57–0.60)  0.38 (0.37–0.39)  
Diastolic pressure ≥77 mm Hg  3.79 (3.29–4.35)  <0.0001  0.66 (0.64–0.69)  0.66 (0.64–0.67)  0.34 (0.33–0.35)  
Prehypertension  5.10 (4.33–6.01)  <0.0001  0.82 (0.80–0.84)  0.53 (0.51–0.54)  0.42 (0.40–0.43)  
Diabetes mellitus  1.79 (1.33–2.40)  0.0001  0.06 (0.05–0.08)  0.96 (0.96–0.97)  0.21 (0.20–0.22)  
Cardiovascular disease  1.26 (0.94–1.70)  0.13  0.05 (0.04–0.07)  0.96 (0.95–0.96)  0.22 (0.21–0.23)  
Smoker  1.46 (1.28– 1.68)  <0.0001  0.39 (0.36–0.42)  0.70 (0.68–0.71)  0.36 (0.35–0.37)  
Alcohol intake  1.95 (1.70–2.24)  <0.0001  0.60 (0.57–0.63)  0.52 (0.50–0.53)  0.43 (0.42–0.45)  
Cholesterol ≥ 5.7 mmol/L   1.84 (1.61–2.10)  <0.0001  0.50 (0.47–0.53)  0.65 (0.64–0.66)  0.38 (0.37–0.39)  
Normotension (<120/<80 mm Hg) and prehypertension (120-139/80-89 mm Hg) refer to the classification based on the conventional blood pressure 
according to JNC72/WHO-ISH3 criteria.  Masked hypertension was a daytime blood pressure of ≥135 mm Hg systolic and/or ≥85 mm Hg diastolic.  
Values are unadjusted odds ratios.  The cutoff points of the predictor variables is based on Younden’s index.   Bracketed values are 95% confidence 
intervals.   
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Table S3 Independent determinants of masked hypertension in 5715 subjects who were normotensive or prehypertensive 
on conventional measurement   
Continuous determinants   Discrete determinants  
 
Odds ratio  P    Odds ratio  P  
Male sex  1.41 (1.21–1.64)  <0.0001   Male sex  1.47 (1.26–1.72)  <0.0001  
Age (+10 years)  1.09 (1.04–1.15)  <0.0001   Age ≥41 years  1.63 (1.37–1.94)  <0.0001  
Body mass index (+5 kg/m2)  1.13 (1.03–1.25)  0.01   BMI ≥25 kg/m2  1.28 (1.10–1.48)  0.001  
Systolic pressure (+10 mm Hg)  1.66 (1.52–1.81)  <0.0001   Systolic pressure ≥120 mm Hg  2.68 (2.27–3.15)  <0.0001  
Diastolic pressure (+5 mm Hg)  1.31 (1.24–1.39)  <0.0001   Diastolic pressure ≥77 mm Hg  2.23 (1.91–2.61)  <0.0001  
Diabetes mellitus  1.52 (1.10–2.10)  0.01   Diabetes mellitus  1.67 (1.22–2.29)  0.002  
Smoker  1.45 (1.25–1.69)  <0.0001   Smoker  1.40 (1.20–1.62)  <0.0001  
Alcohol intake  1.38 (1.18–1.61)  0.0001   Alcohol intake  1.37 (1.18–1.60)  <0.0001  
Cholesterol (+ 1 mmol/L)  1.11 (1.04–1.19)  0.001   Cholesterol ≥5.7 mmol/L  1.27 (1.09–1.47)  0.002  
Normotension (<120/<80 mm Hg) and prehypertension (120-139/80-89 mm Hg) refer to the classification based on the conventional blood pressure according to 
JNC715/WHO-ISH16 criteria.  Masked hypertension was a daytime blood pressure of ≥135 mm Hg systolic and/or ≥85 mm Hg diastolic.  Values are adjusted odds 
ratios.  Odds ratios (95% confidence interval) were adjusted for all the other covariables in the model.  History of cardiovascular disease was not a significant cor-
relate of masked hypertension.  The cutoff points of the discrete predictor variables were based on Younden’s index.   
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Table S4  Multivariable-adjusted hazard ratios for death associated with diastolic ambulatory pressure by category of 
conventional blood pressure  
Endpoints by subgroup  
 24-h   Daytime   Nighttime  
 HR (CI)  P   HR (CI)  P   HR (CI)  P  
Total mortality           
Normotension    0.98 (0.83–1.15)  …   0.92 (0.80–1.07)  …   1.01 (0.89–1.16)  …  
Prehypertension   1.01 (0.92–1.11)  0.75   0.98 (0.91–1.06)  0.57   1.05 (0.98–1.14)  0.64  
Hypertension   1.12 (1.06–1.20)‡  0.13   1.10 (1.04–1.16)†  0.04   1.11 (1.06–1.17)§  0.19  
Cardiovascular mortality           
Normotension   1.10 (0.78–1.54)  …   1.10 (0.82–1.49)  …   0.97 (0.74–1.28)  …  
Prehypertension   1.10 (0.94–1.29)  0.88   1.05 (0.91–1.21)  0.85   1.09 (0.96–1.25)  0.40  
Hypertension   1.24 (1.13–1.35)§  0.39   1.21 (1.11–1.32)§  0.41   1.16 (1.07–1.26)‡  0.24  
Normotension (<120/<80 mm Hg), prehypertension (120-139/80-89 mm Hg) and hypertension (≥140/≥90 mm Hg) refer to the classification based on the 
conventional blood pressure according to JNC715/WHO-ISH16 criteria.  The number of participants and deaths per group appear in Table 2.  Hazard  
ratios (HRs), given with 95% confidence interval (CI) express the risk for a 5-mm Hg increase in diastolic  blood pressure and were adjusted for cohort, sex, 
age, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular complications, and diabetes mellitus.  P values are for the com-
parison of the HRs in prehypertensive and hypertensive participants with the HRs in normotensive subjects.  The differences in the HRs between prehyper-
tensive and hypertensive participants were all nonsignificant (P  0.10) with the exception of total mortality in relation to daytime diastolic blood pressure 
(P = 0.04).  Significance of the hazard ratios: † P   0.01, ‡ P  0.001, and § P  0.0001.  
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Table S5  Multivariable-adjusted hazard ratios for death associated with systolic ambulatory pressure by category  
of conventional blood pressure  
Endpoints by subgroup  
 24-h   Daytime   Nighttime  
 HR (CI)  P   HR (CI)  P   HR (CI)  P  
Total mortality           
Normotension    1.07 (0.87–1.32)  …   0.98 (0.81–1.20)  …   1.08 (0.92–1.28)  …  
Prehypertension   1.09 (0.97–1.22)  0.79   1.03 (0.93–1.15)  0.61   1.13 (1.03–1.24)*  0.66  
Hypertension   1.10 (1.03–1.19)†  0.69   1.07 (0.99–1.15)  0.42   1.10 (1.04–1.17)‡  0.83  
Cardiovascular mortality           
Normotension   1.32 (0.90–1.95)  …   1.30 (0.90–1.86)  …   1.15 (0.82–1.60)  …  
Prehypertension   1.24 (1.02–1.52)  0.87   1.14 (0.96–1.37)  0.99   1.20 (1.02–1.41)*  0.72  
Hypertension   1.32 (1.19–1.46)§  0.78   1.31 (1.18–1.45)§  0.63   1.20 (1.11–1.31)§  0.85  
Normotension (<120/<80 mm Hg), prehypertension (120-139/80-89 mm Hg) and hypertension (≥140/≥90 mm Hg) refer to the classification based on the 
conventional blood pressure according to the JNC715/WHO-ISH16 criteria.  The number of participants and deaths per group appear in Table 2.  Hazard  
ratios (HRs), given with 95% confidence interval (CI) express the risk for a 10-mm Hg increase in systolic blood pressure and were adjusted for cohort, sex, 
age, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular complications, and diabetes mellitus.  P values are for the com-
parison of the HRs in prehypertensive and hypertensive participants with the HRs in normotensive subjects.  The differences in the HRs between prehyper-
tensive and hypertensive participants were all nonsignificant (P   0.37).  Significance of the hazard ratios: * P  0.05; † P  0.01, ‡ P  0.001, and § P  
0.0001.   
 
Risk stratification by CBP and ABP  -s16-   
 
Table S6  Multivariable-adjusted hazard ratios for stroke associated with the diastolic 24-h blood pressure by category of  
conventional blood pressure with one cohort excluded  
Subgroup  
 Normotension   Prehypertension   Hypertension  
 Number  HR (CI)   Number  HR (CI)   Number  HR (CI) 
All cohorts   18/2639  1.98 (1.44–2.74)§   76/3076  1.19 (0.99–1.43)   131/2111  1.28 (1.16–1.41)§  
Excluded cohort           
Ohasama   10/2375  1.47 (0.87–2.48)   43/2648  1.24 (0.97–1.60)   109/1952  1.27 (1.14–1.41)§  
Jingning   18/2522  1.98 (1.44–2.74)§   76/2969  1.19 (0.99–1.43)   128/2036  1.28 (1.16–1.42)§  
Copenhagen   11/2162  3.04 (1.89–4.90)§   57/2363  1.26 (1.02–1.56)*   90/1478  1.27 (1.13–1.43)§  
Dublin   18/2204  1.98 (1.44–2.74)§   75/2713  1.19 (0.99–1.43)*   125/1979  1.31 (1.18–1.45)§  
Noorderkempen   16/2169  1.95 (1.39–2.74)§   71/2597  1.20 (0.99–1.44)   126/1885  1.28 (1.16–1.41)§  
Uppsala   18/2601  1.98 (1.44–2.74)§   61/2836  1.07 (0.87–1.30)   83/1676  1.24 (1.10–1.39)‡  
EPOGH   18/2294  1.98 (1.44–2.74)§   75/2715  1.20 (0.99–1.44)   130/1970  1.29 (1.17–1.42)§  
Montevideo   17/2146  1.94 (1.38–2.74)‡   74/2691  1.22 (1.01–1.47)*   126/1801  1.31 (1.19–1.45)§  
Normotension (<120/<80 mm Hg), prehypertension (120-139/80-89 mm Hg) and hypertension (≥140/≥90 mm Hg) refer to the classification based on the conventional 
blood pressure according to JNC715/WHO-ISH16 criteria.  Number refers to the number of strokes/participants at risk.  Hazard ratios (HR), given with 95% confidence in-
terval (CI) express the risk of stroke for a 5-mm Hg increase in diastolic 24-h blood pressure and were adjusted for cohort, sex, age, body mass index, smoking and 
drinking, serum cholesterol, history of cardiovascular complications, and diabetes mellitus.  Significance of the hazard ratios: * P  0.05; ‡ P  0.001, and § P  0.0001.  
Risk stratification by CBP and ABP  -s17-   
 
Table S7  Multivariable-adjusted hazard ratios for stroke associated with the diastolic daytime blood pressure by category of 
conventional blood pressure with one cohort excluded  
Subgroup  
 Normotension  Prehypertension   Hypertension  
 Number  HR (CI)   Number  HR (CI)   Number  HR (CI)  
All cohorts   18/2639  1.73 (1.29–2.32)‡   76/3076  1.09 (0.93–1.27)   131/2111  1.24 (1.13–1.35)§  
Excluded cohort           
Ohasama   10/2375  1.37 (0.86–2.19)   43/2648  1.05 (0.83–1.32)   109/1952  1.22 (1.11–1.34)§  
Jingning   18/2522  1.73 (1.29–2.32)‡   76/2969  1.09 (0.93–1.27)   128/2036  1.23 (1.13–1.35)§  
Copenhagen   11/2162  2.27 (1.57–3.30)§   57/2363  1.16 (0.97–1.39)   90/1478  1.22 (1.09–1.35)‡  
Dublin   18/2204  1.73 (1.29–2.32)‡   75/2713  1.08 (0.93–1.27)   125/1979  1.25 (1.14–1.37)§  
Noorderkempen   16/2169  1.73 (1.27–2.37)‡   71/2597  1.09 (0.92–1.28)   126/1885  1.23 (1.12–1.35)§  
Uppsala   18/2601  1.73 (1.29–2.32)‡   61/2836  1.01 (0.85–1.20)   83/1676  1.23 (1.10–1.38)‡  
EPOGH   18/2294  1.73 (1.29–2.32)‡   75/2715  1.09 (0.93–1.28)   130/1970  1.24 (1.13–1.36)§  
Montevideo   17/2146  1.68 (1.21–2.32)†   74/2691  1.11 (0.95–1.30)   126/1801  1.27 (1.15–1.39)§  
Normotension (<120/<80 mm Hg), prehypertension (120-139/80-89 mm Hg) and hypertension (≥140/≥90 mm Hg) refer to the classification based on the conventional 
blood pressure according to the JNC715/WHO-ISH16 criteria.  Number refers to the number of strokes/participants at risk.  Hazard ratios (HR), given with 95% confidence 
interval (CI) express the risk of stroke for a 5-mm Hg increase in diastolic daytime blood pressure and were adjusted for cohort, sex, age, body mass index, smoking and 
drinking, serum cholesterol, history of cardiovascular complications, and diabetes mellitus.  Significance of the hazard ratios: † P  0.01, ‡ P  0.001, and § P  0.0001.  
Risk stratification by CBP and ABP  -s18-   
 
Table S8  Multivariable-adjusted hazard ratios for stroke associated with the diastolic 24-h blood pressure by category of  
conventional blood pressure in various strata  
Subgroup  
 Normotension   Prehypertension   Hypertension  
 Number  HR (CI)   Number  HR (CI)   Number HR (CI) 
All cohorts   18/2639  1.98 (1.44–2.74)§   76/3076  1.19 (0.99–1.43)   131/2111  1.28 (1.16–1.41)§  
Women   11/1676  1.95 (1.23–3.10)†   30/1328  1.07 (0.83–1.40)   30/702  1.17 (0.96–1.43)  
Men   7/963  2.88 (1.45–5.70)†   46/1748  1.29 (1.00–1.67)*   101/1409  1.33 (1.18–1.49)§  
<60 years   8/2301  2.02 (1.26–3.24)†   17/2092  1.10 (0.77–1.58)   12/910  1.03 (0.75–1.42)  
60 years   10/338  2.14 (1.24–3.69)†   59/984  1.21 (0.98–1.50)   119/1201  1.33 (1.20–1.48)§  
Asians   8/381  3.44 (1.89–6.25)§   33/535  1.15 (0.88–1.51)   25/234  1.40 (1.06–1.87)*  
Europeans   9/1765  1.26 (0.64–2.45)   41/2156  1.31 (1.01–1.71)*   101/1567  1.31 (1.17–1.46)§  
Normotension (<120/<80 mm Hg), prehypertension (120-139/80-89 mm Hg) and hypertension (≥140/≥90 mm Hg) refer to the classification based on the conventional 
blood pressure according to the JNC715/WHO-ISH16 criteria.  Number refers to the number of strokes/participants at risk.  Hazard ratios (HR), given with 95% confidence 
interval (CI), express the risk of stroke for a 5-mm Hg increase in diastolic 24-h blood pressure and were adjusted for cohort, sex, age, body mass index, smoking and 
drinking, serum cholesterol, history of cardiovascular complications, and diabetes mellitus.  The differences in the HRs between corresponding strata were all nonsignifi-
cant  (P  0.17).  Significance of the hazard ratios: * P  0.05; † P  0.01, and § P  0.0001.  
Risk stratification by CBP and ABP  -s19-   
 
Table S9  Multivariable-adjusted hazard ratios for stroke associated with the diastolic daytime blood pressure by category of 
conventional blood pressure in various strata  
Subgroup  
 Normotension   Prehypertension   Hypertension  
 Number  HR (CI)   Number  HR (CI)   Number  HR (CI) 
All cohorts   18/2639  1.73 (1.29–2.32)‡   76/3076  1.09 (0.93–1.27)   131/2111  1.24 (1.13–1.35)§  
Women   11/1676  1.61 (1.06–2.45)*   30/1328  0.97 (0.77–1.23)   30/702  1.16 (0.97–1.38)  
Men   7/963  2.75 (1.42–5.33)†   46/1748  1.16 (0.93–1.45)   101/1409  1.26 (1.14–1.41)§  
<60 years   8/2301  1.72 (1.12–2.64)*   17/2092  1.08 (0.79–1.48)   12/910  1.15 (0.87–1.53)  
60 years   10/338  1.86 (1.13–3.04)*   59/984  1.08 (0.90–1.30)   119/1201  1.25 (1.14–1.38)§  
Asians   8/381  2.45 (1.58–3.79)§   33/535  1.14 (0.91–1.44)   25/234  1.39 (1.09–1.78)†  
Europeans   9/1765  1.13 (0.62–2.06)   41/2156  1.10 (0.86–1.41)   101/1567  1.25 (1.13–1.39)§  
Normotension (<120/<80 mm Hg), prehypertension (120-139/80-89 mm Hg) and hypertension (≥140/≥90 mm Hg) refer to the classification based on the conventional 
blood pressure according to the JNC715/WHO-ISH16 criteria.  Number refers to the number of strokes/participants at risk.  Hazard ratios (HR), given with 95% confidence 
interval (CI), express the risk of stroke for a 5-mm Hg increase in diastolic daytime blood pressure and were adjusted for cohort, sex, age, body mass index, smoking and 
drinking, serum cholesterol, history of cardiovascular complications, and diabetes mellitus.  The differences in the HRs between corresponding strata were all nonsignifi-
cant  (P  0.09).  Significance of the hazard ratios: * P  0.05; † P  0.01, ‡ P  0.001, and § P  0.0001.  
Risk stratification by CBP and ABP  -s20-   
 
 
 
Figure S1  Hazard ratios for cardiovascular events and stroke associated with masked hypertension on 24-h blood pressure measurement in 
participants with normotension or prehypertension.  Participants with sustained normotension are the reference group.  Normotension 
(<120/<80 mm Hg) and prehypertension (120–139/80–89 mm Hg) refer to the classification based on the conventional blood pressure accord-
ing to JNC715 and WHO-ISH16 criteria.  Thresholds for 24-h hypertension were ≥130 mm Hg systolic or ≥80 mm Hg diastolic.  The hazard rati-
os were adjusted for cohort, sex, age, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular complications, and 
diabetes mellitus.  Horizontal lines denote the 95% confidence interval.  Compared to  prehypertension without masked hypertension, the haz-
ard ratios associated with masked hypertension in prehypertensive subjects were 1.61 (95% confidence interval, 1.27–2.04; P<0.0001) for the 
composite cardiovascular endpoint and 1.63 (1.09–2.42; P = 0.02) for stroke.   
Risk stratification by CBP and ABP  -s21-   
 
 
 
Figure S2  Hazard ratios for cardiovascular events and stroke associated with masked hypertension on nighttime blood pressure measure-
ment in participants with normotension or prehypertension.  Participants with sustained normotension are the reference group.  Normotension 
(<120/<80 mm Hg) and prehypertension (120–139/80–89 mm Hg) refer to the classification based on the conventional blood pressure accord-
ing to the JNC72/WHO-ISH3 criteria.  Thresholds for nighttime hypertension were ≥120 mm Hg systolic or ≥70 mm Hg diastolic.  The hazard ra-
tios were adjusted for cohort, sex, age, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular complications, and 
diabetes mellitus.  Horizontal lines denote the 95% confidence interval.  Compared to  prehypertension without masked hypertension, the haz-
ard ratios associated with masked hypertension in prehypertensive subjects, were 1.46 (95% confidence interval [CI], 1.18–1.88; P=0.0008) for 
the composite cardiovascular endpoint and 1.78 (CI, 1.24–2.56; P = 0.002) for stroke.   
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